Skip to main content
Log in

Diagnosis and treatment of acute promyelocytic leukemia

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Acute promyelocytic leukemia (APL), characterized by a translocation between the promyelocytic leukemia gene (PML) on chromosome 15 and the retinoic acid receptor-α (RARα) gene on chromosome 17, has become a model for targeted treatment of cancer. Advances in our understanding of the fundamental biology of this disease have led to the development of tools for diagnosis, monitoring of minimal residual disease, and detection of early relapse. Differentiation therapy with all-trans retinoic acid in combination with chemotherapy has significantly improved survival in patients with APL. Moreover, arsenic trioxide, which induces differentiation and apoptosis of APL cells, has become standard treatment for relapsed disease, and its role in the treatment of newly diagnosed APL is under active investigation. The lessons learned from APL have broad applications to other forms of leukemia and to cancer in general, whereby molecularly targeted therapy is directed to specifically defined subgroups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Miller WH Jr, Warrell R P Jr, Frankel SR, et al.: Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans retinoic acid. J Natl Cancer Inst 1990, 32:1932–1933.

    Article  Google Scholar 

  2. Huang ME, Ye YC, Chen SR, et al.: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567–572.

    PubMed  CAS  Google Scholar 

  3. Castaigne S, Chomienne C, Daniel MT, et al.: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990, 76:1704–1709.

    PubMed  CAS  Google Scholar 

  4. Warrell RP Jr, Frankel SR, Miller WH Jr, et al.: Differentiation therapy of acute promyelocytic leukemia with treatinoin (all-trans-retinoic acid). N Engl J Med 1991, 324:1385–1393.

    Article  PubMed  Google Scholar 

  5. Tallman MS, Andersen JW, Schiffer CA, et al.: All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002, 100:4298–4302.

    Article  PubMed  CAS  Google Scholar 

  6. Shen Z-X, Chen G-Q, Ni J-H, et al.: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapse patients. Blood 1997, 89:3345–3360.

    Google Scholar 

  7. Dombret H, Scrobohaci ML, Daniel MT, et al.: In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): Effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995, 9:19–24.

    PubMed  CAS  Google Scholar 

  8. Menell JS, Cesarman GM, Jacovina AT, et al.: Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999, 340:994–1004.

    Article  PubMed  CAS  Google Scholar 

  9. Golomb HM, Rowley JD, Vardiman JW, et al.: Micro-granular acute promyelocytic leukaemia: A distinct clinical, ultrastructural, and cytogenetic entity. Blood 1980, 55:253–259.

    PubMed  CAS  Google Scholar 

  10. Sainty D, Liso V, Cantu-Rajnoldi A, et al.: A new morphological classification system for acute promyelocytic distinguishes cases with underlying PLZF-RARα rearrangements. Blood 2000, 96:1287–1296.

    PubMed  CAS  Google Scholar 

  11. Vahdat L, Maslak P, Miller WH, et al.: Early mortality and retinoic acid syndrome in acute promyelocytic leukemia: impact of leucocytosis, low-dose chemotherapy, PML/RARα isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994, 84:3843–3849.

    PubMed  CAS  Google Scholar 

  12. Ferrara F, Morabito F, Martino B, et al.: CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous ATRA and chemotherapy. J Clin Oncol 2000, 18:1295–1300.

    PubMed  CAS  Google Scholar 

  13. Jurcic JG, Nimer SD, Scheinberg D, et al.: Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001, 98:2651–2656.

    Article  PubMed  CAS  Google Scholar 

  14. Stock W, Moser B, Sher DA, et al.: PML-RARα isoform at diagnosis is associated with disease-free survival in patients enrolled in the intergroup trial (C-9710) for treatment of acute promyelocytic leukemia [abstract]. Proc ASCO 2006, 24:338s.

    Google Scholar 

  15. Slack JL, Arthur DC, Lawrence D, et al.: Secondary cytogenetic changes in acute promyelocytic leukemia: prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene. A Cancer and Leukemia Group B study. J Clin Oncol 1997, 15:1786–1795.

    PubMed  CAS  Google Scholar 

  16. Grimwade D, Biondi A, Mozziconacci MJ, et al.: Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood 2000, 96:1297–1308.

    PubMed  CAS  Google Scholar 

  17. Chen S-J, Zelent A, Tong J-H, et al.: Rearrangements of the retinoic acid receptor alpha and promyelocytic zinc finger genes resulting from t(11;17)(q23;q21) in a patients with acute promyelocytic leukemia. J Clin Invest 1993, 91:2260–2267.

    Article  PubMed  CAS  Google Scholar 

  18. Redner RL, Rush EA, Faas S, et al.: The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosminretinoic acid receptor fusion. Blood 1996, 87:882–886.

    PubMed  CAS  Google Scholar 

  19. Wells RA, Catzavelos C, Kamel-Reid S: Fusion of retinoic acid receptor alpha to NUMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia. Nat Genet 1997, 17:109–113.

    Article  PubMed  CAS  Google Scholar 

  20. Arnould C, Philippe C, Bourdon V, et al.: The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukemia. Human Mol Genet 1999, 8:1741–1749.

    Article  CAS  Google Scholar 

  21. Heinzel T, Lavinski R, Mullen T, et al.: A complex containing N-CoR, mSin3 and histone deacetylase, mediates transcriptional repression. Nature 1997, 387:43–48.

    Article  PubMed  CAS  Google Scholar 

  22. Matsushita H, Scaglioni PP, Bhaumik M, et al.: In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia. J Exp Med 2006, 203:821–828.

    Article  PubMed  CAS  Google Scholar 

  23. Rego EM, Zhu-Gang W, Peruzzi D, et al.: Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med 2001, 193:521–529.

    Article  PubMed  CAS  Google Scholar 

  24. Miller WH Jr, Kakizuka A, Frankel SR, et al.: Reverse transcription polymerase chain reaction for the re-arranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992, 89:2694–2698.

    Article  PubMed  CAS  Google Scholar 

  25. Lo Coco F, Diverio D, Pandolfi PP, et al.: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 1992, 340:1437–1438.

    Article  Google Scholar 

  26. Esteve J, Escoda L, Martin G, et al.: Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007, 21:446–452.

    Article  PubMed  CAS  Google Scholar 

  27. Liu YF, Zhu YM, Shen SH, et al.: Molecular response in acute promyelocytic leukemia: a direct comparison of regular and real-time RT-PCR. Leukemia 2006, 20:1393–1399.

    Article  PubMed  CAS  Google Scholar 

  28. Santamaria C, Chillon MC, Fernandez C, et al.: Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica 2007, 92:315–322.

    PubMed  CAS  Google Scholar 

  29. Fenaux P, Castaigne S, Dombret H, et al.: All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remission in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992, 80:2176–2181.

    PubMed  CAS  Google Scholar 

  30. Fenaux P, Chastang C, Chevret S, et al.: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999, 94:1192–1200.

    PubMed  CAS  Google Scholar 

  31. Mandelli F, Diverio D, Avvisati G, et al.: Molecular remission in PML/RARalpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997, 90:1014–1021.

    PubMed  CAS  Google Scholar 

  32. Sanz MA, LoCoco F, Martin G, et al.: Definition of relapse risk and role of non anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96:1247–1253.

    PubMed  CAS  Google Scholar 

  33. Sanz MA, Martin G, González M, et al.: Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracyclines monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004, 103:1237–1243.

    Article  PubMed  CAS  Google Scholar 

  34. Adés L, Chevret S, Raffoux E, et al.: Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006, 24:5703–5710.

    Article  PubMed  CAS  Google Scholar 

  35. Chen G-Q, Zhu J, Shi X-G, et al.: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996, 88:1052–1061.

    PubMed  CAS  Google Scholar 

  36. Chen G, Shi X, Tang W, et al.: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose dependent dual effects on APL cells. Blood 1997, 89:3345–3353.

    PubMed  CAS  Google Scholar 

  37. Soignet SL, Maslak PM, Wang Z-G, et al.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341–1348.

    Article  PubMed  CAS  Google Scholar 

  38. Soignet SL, Frankel SR, Douer D, et al.: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852–3860.

    PubMed  CAS  Google Scholar 

  39. Rego EM, He LZ, Warrell RP Jr, et al.: Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RAR alpha and PLZF-RAR alpha oncoproteins. Proc Natl Acad Sci U S A 2000, 97:10173–10178.

    Article  PubMed  CAS  Google Scholar 

  40. Shen Z-X, Shi Z-Z, Fang J, et al.: All-trans retinoic acid/As2O3 combinations yield a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004, 101:5328–5335.

    Article  PubMed  CAS  Google Scholar 

  41. Estey EH, Garcia-Manero G, Ferrajoli A, et al.: Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006, 107:3469–3473.

    Article  PubMed  CAS  Google Scholar 

  42. Jurcic JG: Antibody therapy for residual disease in acute myelogenous leukemia. Crit Rev Oncol Hematol 2001, 38:37–45.

    Article  PubMed  CAS  Google Scholar 

  43. Mulford DA, Maslak PG, Weiss MA, et al.: Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy [abstract]. Blood 2003, 102:619a–620a.

    Google Scholar 

  44. Estey EH, Giles FJ, Beran M, et al.: Experience with gemtuzumab ozogamicin (“Mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002, 99:4222–4224.

    Article  PubMed  CAS  Google Scholar 

  45. Tsimberidou AM, Tirado-Gomez M, Andreeff M, et al.: Single-agent all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M.D. Anderson Cancer Center series. Leuk Lymphoma 2006, 47:1062–1068.

    Article  PubMed  CAS  Google Scholar 

  46. Adamson PC, Bailey J, Pluda J, et al.: Pharmacokinetics of all-trans retinoic acid administered on an intermittent schedule. J Clin Oncol 1995, 13:1238–1241.

    PubMed  CAS  Google Scholar 

  47. Douer D, Hu W, Giralt S, Lill M, DiPersio J. Arsenic trioxide (Trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003, 8:132–140.

    Article  PubMed  CAS  Google Scholar 

  48. deBotton S, Fawaz A, Chevret S, et al.: Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2005, 23:120–126.

    Article  CAS  Google Scholar 

  49. Meloni G, Diverio D, Vignetti M, et al.: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997, 90:1321–1325.

    PubMed  CAS  Google Scholar 

  50. deBotton S, Sanz MA, Chevret S, et al.: Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006, 20:35–41.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joseph G. Jurcic MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jurcic, J.G., Soignet, S.L. & Maslak, P.G. Diagnosis and treatment of acute promyelocytic leukemia. Curr Oncol Rep 9, 337–344 (2007). https://doi.org/10.1007/s11912-007-0045-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0045-9

Keywords

Navigation